EXACT Therapeutics AS — Share Issue/Capital Change 2021

Jun 7, 2021

EXACT Therapeutics AS: Share Capital Increase

EXACT Therapeutics AS: Share Capital Increase

Oslo, 7 June 2021 – The Board of Directors of EXACT Therapeutics AS (the "Company") has resolved on June 4th 2021 to increase the share capital of the Company by NOK 97.668 through the issuance of 24,427 new shares.

The new shares are issued pursuant to the authorisation provided to the Board of Directors at the Annual General Meeting in 2020, for the purpose of issuing shares under the Company's restricted stock unit (RSU) program to its board members. The shares are issued at a price of NOK 20.804 per share, which equals the market price of the share in the last private placement of the Company.

Following the share capital increase, the Company will have a share capital of NOK 119,968.668 divided into 29,992,167 shares, each with a nominal value of NOK 0.004.

DISCLOSURE REGULATION

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About EXACT-Tx

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com